News Wire

Analysts at Thomson Reuters have issued a report detailing seven drugs that will likely hit blockbuster status this year—defined as earning more than $1 billion annually. These treatments are listed below. Obeticholic Acid for Liver Disease The farnesoid X receptor agonist obeticholic acid (Intercept…
Rural hospitals have been on the brink of financial disaster for years, but it now seems that state and federal lawmakers may finally be willing to help. Since 2010, 71 rural hospitals have closed, driven by congressional spending measures that cut Medicare payments and by the Patient Protection and…
During the past 20 years, advances in routine care have allowed many people with sickle cell anemia to live into middle age and beyond. But early adulthood, a time when patients make a switch from pediatric to adult care, can be perilous for these individuals, according to a report from Kaiser Health…
The FDA has issued draft guidance intended to support the pharma industry in its development of generic versions of approved opioids with abuse-deterrent formulations (ADFs) while ensuring that generic ADF opioids are no less abuse-deterrent than the brand-name drug. The new guidance is among a number…
Mixed findings have been reported from the phase 3 APEX (Acute Medically Ill VTE Prevention With Extended-Duration BetriXaban) study, which evaluated the superiority of extended-duration anticoagulation with oral betrixaban (Portola Pharmaceuticals) compared with standard-of-care anticoagulation with…
The first head-to-head superiority study of two treatments in the anti-tumor necrosis factor (TNF) class has failed to meet its primary endpoints for superiority. The phase 4 study compared certolizumab pegol (Cimzia, UCB) plus methotrexate (MTX) with adalimumab (Humira, AbbVie) plus MTX in adults with…
Hackers have demanded a ransom from two more Southern California hospitals and federal authorities are investigating the case, according to a report from Kaiser Health News. Prime Healthcare Services Inc., a national hospital chain, said the attackers infiltrated computer servers at two of its California…
March 24 marks the day in 1882 when German microbiologist Robert Koch announced he had discovered Mycobacterium tuberculosis (Mtb), the bacterium that causes TB. Today, more than a century later, TB remains one of the world’s deadliest diseases, according to a new report from the National Institute…
The FDA has given the green light to reslizumab (Cinqair, Teva Pharmaceuticals) for use with other asthma medications for the maintenance treatment of severe asthma in patients 18 years of age and older. Reslizumab is approved for patients who have a history of severe asthma attacks (exacerbations)…
Positive results have been reported from a phase 3 trial evaluating alirocumab (Praluent, Sanofi) injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH), whose cholesterol levels required chronic weekly or biweekly apheresis therapy.…
The FDA has announced required class-wide safety labeling changes for immediate-release (IR) opioid pain medications. Among the changes, the FDA is requiring a new boxed warning about the serious risks of misuse, abuse, addiction, overdose, and death. The agency is also requiring several additional…
The FDA has approved ixekizumab (Taltz, Eli Lilly) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Ixekizumab is designed to specifically target interleukin-17A, a protein that plays a role in driving…
A new guideline from the American Cancer Society (ACS) provides clinicians with recommendations on key areas of clinical follow-up care for survivors of head-and-neck cancer—a growing population numbering approximately 436,060 individuals and accounting for 3% of all cancer survivors in the United…
Despite being costly and of little proven benefit, a procedure for treating pulmonary embolism with blood clot filters is routinely used in older adults, Yale School of Medicine researchers have found. Published in the Journal of the American College of Cardiology, the study also showed that the utilization…
AstraZeneca has announced the results from the pivotal SOCRATES trial, which assessed the efficacy of ticagrelor (Brilinta) 90 mg twice daily compared with aspirin 100 mg once daily in patients with acute ischemic stroke (AIS) or transient ischemic attack (TIA). The primary efficacy endpoint of the…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA